Dr. Abid on the Potential Impact of CAR T-Cell Therapy on COVID-19 Vaccination

Video

Muhammad Bilal Abid, MD, MRCP, discusses the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.

Muhammad Bilal Abid, MD, MRCP, assistant professor of medicine, Divisions of Hematology/Oncology and Infectious Diseases, Medical College of Wisconsin, discusses the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.

Patients who undergo CAR T-cell therapy should be revaccinated for COVID-19 following infusion, because the treatment may cause them to lose their response to the vaccine, according to Abid.

Additionally, it has been shown that if the patient received the COVID-19 vaccine within 6 months of receiving CAR T-cell infusion, response rates were not as favorable, Abid explains. Patients who received the vaccination more than 6 months after infusion have improved response rates, likely because they have better immune reconstitution, Abid concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD